DOCSLIB.ORG

(2) Patent Application Publication (10) Pub. No.: US 2017/0020873 A1 Mitchell (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(2) Patent Application Publication (10) Pub. No.: US 2017/0020873 A1 Mitchell (43) Pub US 20170020873A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2017/0020873 A1 Mitchell (43) Pub. Date: Jan. 26, 2017 (54) PHARMACEUTICAL COMPOSITIONS Publication Classification (71) Applicant:: …~~~ +. *e Inc., Arlington,- (51) A61RInt. Cl. 31/.505 (2006.01) A61 K. 3 1/137 (2006.01) (72) Inventor: Odes W. Mitchell, Arlington, TX (US) A61 K. 3 1/167 (2006.01) A61 K. 3 1/09 (2006.01) - A61 K 37/495 (2006.01) (21)21) Appl. No.:No 15/287,047s A61 K 31/485 (2006.01) 31, 21. A61 K. 3 1/135 (2006.01) (22) Filed: Oct. 6, 2016 A61 K. 3 I/4402 (2006.01) Related U.S. Application- - - Dat ( 52) U.S. CI. elate pplication Data CPC ........... A61K 31/505 (2013.01); A61K 31/135 (63) Continuation of application No. 14/733,731, filed on (2013.01); A61K 31/137 (2013.01); A61 K Jun. 8, 2015, now Pat. No. 9,463,191, which is a 31/4402 (2013.01); A61K 31/09 (2013.01); continuation of application No. 13/703,584, filed on A61K 31/495 (2013.01); A61K 31/485 Feb. 2, 2013, now Pat. No. 9,050,289, filed as appli- (2013.01); A61K 31/167 (2013.01) cation No. PCT/US2011/040231 on Jun. 13, 2011. (60) Provisional application No. 61/354,053, filed on Jun. (57) ABSTRACT 11, 2010, provisional application No. 61/354,057, A composition of an antitussive, a decongestant, or an filed on Jun. 11, 2010, provisional application No. antihistamine to treat upper respiratory and oral pharyngeal 61/354,061, filed on Jun. 11, 2010. congestion and related symptoms in a patient. US 2017/0020873 A1 Jan. 26, 2017 chloride, diprodualone camsilate, dixyrazine, doxylamine metaraminol, phenylephrine, tyraine, hydroxyamphetamine, succinate, eprozinol dihydrochloride, etodroxizine ritodrine, prenalterol, methoxyamine, albuterol, amphet dimaleate, etybenzatropine bromhydrate, etybenzatropine amine, methamphetamine, benzphetamine, ephedrine, phe hydrochloride, etymemazine hydrochloride, fenethazine nylpropanolamine, mephentermine, phentermine, fenflu hydrochloride, fenoxazoline hydrochloride, fenpentadiol, ramine, propylhexedrine, diethylpropion, phenmetrazine, flunarizine hydrochloride, flupentixol decanoate, flupentixol phendimetrazine, oxymetazoline, xylometazoline, and pseu dihydrochloride, histapyrrodine hydrochloride, hydroxyzine doephedrine. dihydrochloride, hydroxyzine embonate, indoramine hydro [0020] It should be understood that an effective amount of chloride, isothipendyl hydrochloride, ketotifene fumarate, the antitussive and the decongestant generally vary with the levocabastine hydrochloride, levomepromazine, levomepro particular antitussive and decongestant chosen. In addition, mazine hydrochloride, levomepromazine embonate, an effective amount depends upon many other factors, such levomepromazine maleate, loratadine, maprotiline hydro as known differences in pharmacokinetic parameters (ab chloride, maprotiline mesilate, maprotiline resinate, sorption, distribution and clearance) regardless of the cause. meclozine hydrochloride, mecysteine hydrochloride, medi For example, in a patient with a renal dysfunction or foxamine fumarate, mefenidramium metilsulfate, mepyra disorder, the effective dose of the antihistamine, the antitus mine maleate, meduitazine, methaqualone, methdilazine sive, and the decongestant is generally half of an effective hydrochloride, metixene hydrochloride, mizolastine, moxi dose for a patient without renal dysfunction. sylyte hydrochloride, niaprazine, orphenadrine hydrochlo [0021] While the present composition includes an antitus ride, oxaflumazine disuccinate, oxatomide, oxolamine ben sive, a decongestant, and an antihistamine, the present zilate, oxolamine citrate, oxomemazine, oxomemazine composition is not so limited and may include other com hydrochloride, parathiazine teoclate, perimetazine, pheni ponents. These components include conventional excipients, ramine maleate, phenoxybenzamine hydrochloride, phenyl useful and/or desirable to render the composition suitable or toloxamine, phenyltoloxamine citrate, pimethixene, pipoti attractive for consumption and use. Excipients providing azine, pipretecol dihydrochloride, pizotifene malate, physical and aesthetic properties for formulation or delivery prednazoline, profenamine hydrochloride, promethazine, of the composition are desirable. For example, with respect promethazine hydrochloride, promethazine embonate, pro to physical properties, ingredients imparting desirable and methazine polyvinylbenzene-metacrylate, propiomazine, acceptable hardness, disintegration properties, dissolution terfenadine, thenalidine tartrate, thenyldiamine hydrochlo rate for release of therapeutic components, stability, and size ride, thiazinamium metilsulfate, thonzylamine hydrochlo to effectively deliver the composition may be included. ride, tripelennamine hydrochloride, triprolidine hydrochlo Disintegrants may be included for the purposes of facilitat ride, and tymazoline hydrochloride, and combinations ing the breakup of a tablet after the tablet is administered to thereof. the patient. Examples of disintegrants include, but are not [0017] The antihistamine is included in an amount, per limited to, modified or unmodified starches such as corn dosage of the composition, sufficient to alleviate one or more starch, potato starch, wheat starch, or sodium cross-carmel histamine-mediated responses in a patient. Effective doses los. With respect to aesthetics, it may be desirable for the of the antihistamine will generally vary depending upon the composition to contain additives that appeal to the human antihistamine (s) administered. senses such as colorants, fragrances, texture modifiers, and/ [0018] The present composition also includes an antitus or flavorants. Additionally, many flavoring agents such as, sive. The term “antitussive”, as used herein, is intended to for example, fruit flavors, or sweeteners, such as sodium include any agent or active ingredient effective for cough saccharin, confectionery sugar, sucrose, xylitol, or combi suppression such as chlophedianol hydrochloride. These nations thereof, may be included. Additionally, suitable also include, but are not limited to, common opioid analge colorants including, for example, red beet powder, ferric sics such as hydrocodone, codeine, morphine, morphine oxide, FD&C dyes, or combinations thereof, may be related compounds including diacetylmorphine, oxymor included in the present compositions. Desirable excipients phone, hydromorphone, dextromethorphan, levorphanol, may also include buffering agents, surfactants, electrolytes, oxycodone, nalmefene, methadone, meperidine, pentazo and thixotropic agents. It should be understood that these cine, buprenorphine, nalbuphine, butorphanol, sufentanyl, other components should not affect the action or mechanism alfentanyl and propoxyphene, and opioid antagonists not of action of the antitussive, decongestant, and/or the anti structurally-related to morphine, such as nalorphine, nalox histamine in the composition. one, maltrexone and fentanyl. In one embodiment, the anti [0022] Excipients or formulations affecting the release tussive agent is hydrocodone or a pharmaceutically accept properties, mechanisms, and/or rates of the antitussive, the able salt form thereof, such as hydrocodone bitartrate. decongestant, and the antihistamine, from the composition [0019] The present composition also includes a deconges upon oral ingestion may be provided. For example, the tant. The term “decongestant” as used herein, is intended to composition may be formulated such that the release of the refer to any agent or ingredient, active for reducing or antitussive, the decongestant, and/or the antihistamine or eliminating congestion of the air passages by widening the other active ingredients from the composition is delayed for airway, and/or by stimulating the release of phlegm and a period of time or to survive a particular environment. mucus from these passages. Air passages may be widened by [0023] Advantageously, the composition may be formu reducing the swelling of the mucous membranes in the lated so as to prevent the release of the antitussive, the passage. Generally, sympathomimetic drugs have deconges decongestant, and/or the antihistamine in the stomach where tant properties. Examples of suitable decongestants include, they may likely be acidified, salted out and excreted from the without limitation, phenylethylamine, epinephrine, norepi body rather than absorbed into the circulation. For example, nephrine, dopamine, dobutamine, colterol, ethylnorepineph the composition may be coated with a coating to improve rine, isoproterenol, isoetharine, metaproterenol, terbutaline, absorption and render the composition more bioavailable US 2017/0020873 A1 Jan. 26, 2017 than it would otherwise be without the coating. Enteric and other blockage of air passages, the composition of the coatings or encapsulation-type coatings as known to one present invention includes the antitussive, the decongestant, skilled in the art are suitable for this purpose. In one and the antihistamine in amounts suitable for treating chil embodiment, a table or a capsule form of the composition is dren and adults alike. enterically coated so as to provide delayed-release and [0028] In yet another embodiment of the present inven sustained-release properties to the composition. Sustaining tion, there is provided methods of alleviating symptoms of upper respiratory and oral pharyngeal congestion by orally the release of individual active ingredients to the body over administering to a patient in need thereof a single dose of
Load more

Recommended publications
  • Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More Information
    Cambridge University Press 978-0-521-86781-8 - Core Topics in Mechanical Ventilation Edited by Iain Mackenzie Index More information Index Abdominal distension in lung elastance oxygen toxicity 270 incidence data 240 345, 346 patient assessment 118, 115–119, 120 laryngeal injuries 248, 247–248 Abdominal paradox 27 recruitment manoeuvres 118–119, left ventricular performance 273 N-Acetylcysteine 79–80, 81, 357, 358 131, 219 lorazepam 165 Acinetobacter baumanii, SDD for 260 trials (See ARDS net trials) lung injury, ventilator-associated (See Acute hypoxaemic respiratory failure ventilation management Lung injury, defined 115 HFOV 127–131, 305–306 ventilator-associated) Acute lung injury (ALI) IRV 125–126 maxillary sinusitis/middle ear blast injuries 212 liquid 228 effusions 246–247 hypoxaemia, PEEP management of modes 215–216 midazolam 165 124–125 overview 214 nasopharyngeal airways 243–245, infants/children 300–301 principles 214–215, 216 246–247 liquid ventilation 228 Acute respiratory failure (ARF) nasotracheal intubation 315 patient assessment 118, 115–119, clinical presentation 29 neurological function 277, 276–277, 120, 197 mechanisms of 24 278, 280 recruitment manoeuvres 131, 219 NIV 43, 49–50 (See also Non-invasive NMBAs 171, 176–177, 276–280 ventilation management ventilation (NIV)) NSAIDs 181 HFV 149–150 overview 24, 22–24, 25, 142 opioid agonists 180 IRV 125–126 Adaptive support ventilation® 113, 361 opioids 276–280 modes 215–216 Adrenaline 81 overview 21, 239, 241 overview 214 Adrenergic receptor antagonists 349, oxygen toxicity
    [Show full text]
  • PROZAC Product Monograph Page 1 of 49 Table of Contents
    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]